

3.1 患者背景

3.1.1 患者背景一覧表

患者背景		血縁者間 骨髄移植	血縁者間末梢血 幹細胞移植	非血縁者間 骨髄移植	臍帯血移植	合計
患者数		3,349	5,424	9,765	8,193	26,731
性別	男性	1,882 (56.2%)	3,183 (58.7%)	5,856 (60.0%)	4,841 (59.1%)	15,762 (59.0%)
	女性	1,467 (43.8%)	2,241 (41.3%)	3,907 (40.0%)	3,349 (40.9%)	10,964 (41.0%)
	不明・未記載	0 (0.0%)	0 (0.0%)	2 (0.0%)	3 (0.0%)	5 (0.0%)
年齢	0-17	1,121 (33.5%)	505 (9.3%)	1,229 (12.6%)	1,389 (17.0%)	4,244 (15.9%)
	18-55	1,720 (51.4%)	3,507 (64.7%)	5,637 (57.7%)	3,962 (48.4%)	14,826 (55.5%)
	56-	508 (15.2%)	1,412 (26.0%)	2,899 (29.7%)	2,841 (34.7%)	7,660 (28.7%)
	不明・未記載	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.0%)	1 (0.0%)
診断	AML	1,038 (31.0%)	2,283 (42.1%)	3,615 (37.0%)	3,605 (44.0%)	10,541 (39.4%)
	ALL	808 (24.1%)	941 (17.4%)	1,815 (18.6%)	1,429 (17.4%)	4,993 (18.7%)
	ATL	103 (3.1%)	222 (4.1%)	539 (5.5%)	324 (4.0%)	1,188 (4.4%)
	CML	76 (2.3%)	110 (2.0%)	240 (2.5%)	195 (2.4%)	621 (2.3%)
	MDS	306 (9.1%)	436 (8.0%)	1,193 (12.2%)	770 (9.4%)	2,705 (10.1%)
	NHL	255 (7.6%)	781 (14.4%)	982 (10.1%)	830 (10.1%)	2,848 (10.7%)
	固形腫瘍	70 (2.1%)	65 (1.2%)	14 (0.1%)	175 (2.1%)	324 (1.2%)
	その他	693 (20.7%)	586 (10.8%)	1,367 (14.0%)	865 (10.6%)	3,511 (13.1%)
移植時病期	CR	1,574 (47.0%)	2,150 (39.6%)	4,988 (51.1%)	3,290 (40.2%)	12,002 (44.9%)
	Non-CR	1,147 (34.3%)	2,948 (54.4%)	3,920 (40.1%)	4,273 (52.2%)	12,288 (46.0%)
	その他	532 (15.9%)	191 (3.5%)	699 (7.2%)	482 (5.9%)	1,904 (7.1%)
	不明・未記載	96 (2.9%)	135 (2.5%)	158 (1.6%)	148 (1.8%)	537 (2.0%)
BU剤型	BU(経静脈)を含むレジメン	783 (94.2%)	1,818 (91.8%)	3,285 (92.9%)	2,064 (94.7%)	7,950 (93.2%)
	BU(経口)を含むレジメン	48 (5.8%)	163 (8.2%)	251 (7.1%)	116 (5.3%)	578 (6.8%)
前治療レジメン	BU(経静脈)+CY±other	300 (13.2%)	443 (11.5%)	917 (11.4%)	280 (4.1%)	1,940 (9.3%)
	CY+TBI±other	1,095 (48.1%)	1,213 (31.4%)	3,127 (38.8%)	2,082 (30.8%)	7,517 (35.8%)
	BU(経静脈)+FL±other	417 (18.3%)	1,308 (33.9%)	2,290 (28.4%)	1,681 (24.8%)	5,696 (27.2%)
	FL+TBI±other	466 (20.5%)	899 (23.3%)	1,733 (21.5%)	2,725 (40.3%)	5,823 (27.8%)
GVHD予防薬	MTX+CyA	1,923 (57.4%)	2,370 (43.7%)	1,346 (13.8%)	1,752 (21.4%)	7,391 (27.7%)
	MTX+FK506	915 (27.3%)	1,201 (22.1%)	7,744 (79.3%)	2,945 (36.0%)	12,805 (47.9%)
	その他	511 (15.3%)	1,853 (34.2%)	675 (6.9%)	3,496 (42.7%)	6,535 (24.5%)

* 生存が不明の症例(91例)と最終生死確認日が不明の症例(9例)を以後の解析から除いた。

* 移植時病期のCRには、悪性リンパ腫のPR、多発性骨髄腫のPR、慢性リンパ性白血病のPRも含む。

3.1.2 略語一覧

略語		
ARDS	Acute respiratory distress syndrome	急性呼吸促進症候群
BU	Busulfan	ブスルファン
CY	Cyclophosphamide	シクロホスファミド
CyA	Cyclosporin A	シクロスポリンA
FK506	Tacrolimus	タクロリムス
FL	Fludarabine phosphate	フルダラビン
GVHD	Graft versus host disease	移植片対宿主病
iv	Intravenous	経静脈
MTX	Methotrexate	メトトレキサート
PTLD	Post-transplantation lymphoproliferative disorder	移植後リンパ増殖性疾患
SD	Standard deviation	標準偏差
TBI	Total body irradiation	全身放射線照射
TMA	Thrombotic microangiopathy	血栓性微小血管障害
VOD	Veno-occlusive disease	肝中心静脈閉塞症

* その他の略語は、移植アウトカムの解析の略語一覧にあります。